NICE new T2D drugs
May 27, 2016
PEOPLE living with type 2
diabetes (T2D) will now be eligible
for three new therapy options
under new guidelines released
by the UK’s National Institute for
Health and Care Excellence (NICE).
The new ruling has the potential
to improve glucose control in
around 31,000 people, NICE
has said, naming canagliflozin
(Invokana), dapagliflozin (Forxiga)
and empagliflozin (Jardiance) as
improved treatment options.
In the UK, almost 3.5 million
people have been diagnosed with
diabetes and it’s estimated that
about 90% of adults with the
condition have type 2 diabetes.
The new therapies will help
those unable to take metformin,
sulfonylurea or pioglitazone, a NICE
statement explained.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 May 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 May 16